$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415047733 Filed on August 10, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$2.163M	$1.162M
YoY Change	86.14%	60.94%
Cost Of Revenue	$1.197M	$729.0K
YoY Change	64.2%	25.91%
Gross Profit	$966.0K	$433.0K
YoY Change	123.09%	202.8%
Gross Profit Margin	44.66%	37.26%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$2.366M	$4.020M
YoY Change	-41.14%
% of Gross Profit	244.95%	928.48%
Depreciation & Amortization	$161.5K	$209.4K
YoY Change	-22.89%	91.14%
% of Gross Profit	16.71%	48.36%
Operating Expenses	$3.373M	$4.864M
YoY Change	-30.65%	335.06%
Operating Profit	-$2.407M	-$4.431M
YoY Change	-45.68%	354.0%
Interest Expense	$76.23K	$78.21K
YoY Change	-2.53%	4.58%
% of Operating Profit
Other Income/Expense, Net	$7.139M	$2.338M
YoY Change	205.35%	11.6%
Pretax Income	$4.735M	-$4.402M
YoY Change	-207.57%	-577.59%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$4.732M	-$2.094M
YoY Change	-325.98%	-327.11%
Net Earnings / Revenue	218.77%	-180.21%
Basic Earnings Per Share	$0.02	-$0.01
Diluted Earnings Per Share	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	646.9M shares	565.2M shares
Diluted Shares Outstanding	812.6M shares	733.9M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.62M	$8.170M
YoY Change	42.23%	3452.17%
Cash & Equivalents	$11.62M	$8.173M
Short-Term Investments
Other Short-Term Assets	$260.0K	$220.0K
YoY Change	18.18%	83.33%
Inventory	$2.860M	$2.530M
Prepaid Expenses
Receivables	$1.050M	$1.170M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$15.78M	$12.08M
YoY Change	30.63%	576.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.950M	$4.950M
YoY Change	40.4%	25.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$180.0K	$20.00K
YoY Change	800.0%	-99.4%
Other Assets	$600.0K	$584.9K
YoY Change	2.58%	-0.86%
Total Long-Term Assets	$14.13M	$11.89M
YoY Change	18.86%	38.12%
TOTAL ASSETS
Total Short-Term Assets	$15.78M	$12.08M
Total Long-Term Assets	$14.13M	$11.89M
Total Assets	$29.91M	$23.97M
YoY Change	24.79%	130.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.490M	$3.210M
YoY Change	-22.43%	150.78%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$410.0K	$620.0K
YoY Change	-33.87%
Long-Term Debt Due	$450.0K	$3.480M
YoY Change	-87.07%	-12.78%
Total Short-Term Liabilities	$4.360M	$7.310M
YoY Change	-40.36%	37.66%
LONG-TERM LIABILITIES
Long-Term Debt	$2.070M	$0.00
YoY Change
Other Long-Term Liabilities	$15.15M	$101.1M
YoY Change	-85.02%	107667.9%
Total Long-Term Liabilities	$41.87M	$101.1M
YoY Change	-58.59%	780.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.360M	$7.310M
Total Long-Term Liabilities	$41.87M	$101.1M
Total Liabilities	$21.58M	$108.4M
YoY Change	-80.1%	545.65%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	100.0K shares	100.0K shares
Shareholders Equity	$8.330M	-$84.45M
YoY Change
Total Liabilities & Shareholders Equity	$29.91M	$23.97M
YoY Change	24.78%	130.66%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	$4.732M	-$2.094M
YoY Change	-325.98%	-327.11%
Depreciation, Depletion And Amortization	$161.5K	$209.4K
YoY Change	-22.89%	91.14%
Cash From Operating Activities	$1.890M	-$4.210M
YoY Change	-144.89%	1085.76%
INVESTING ACTIVITIES
Capital Expenditures	-$720.0K	-$690.0K
YoY Change	4.35%	1280.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$4.930M
YoY Change	-100.0%	-6262.5%
Cash From Investing Activities	-$720.0K	$4.240M
YoY Change	-116.98%	-3243.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.041M	$896.6K
YoY Change	127.59%	124.15%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.980M	1.200M
YoY Change	148.33%	240.9%
NET CHANGE
Cash From Operating Activities	1.890M	-4.210M
Cash From Investing Activities	-720.0K	4.240M
Cash From Financing Activities	2.980M	1.200M
Net Change In Cash	4.150M	1.230M
YoY Change	237.4%	-991.81%
FREE CASH FLOW
Cash From Operating Activities	$1.890M	-$4.210M
Capital Expenditures	-$720.0K	-$690.0K
Free Cash Flow	$2.610M	-$3.520M
YoY Change	-174.15%	1053.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	41870188	USD
CY2014Q2	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	949037	USD
CY2015Q2	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1675773	USD
CY2014Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	207645	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2014Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	193885	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	1196968	USD
CY2014Q2	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
CY2015Q2	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	5882804	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2366262	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1161682	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	7079772	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	728530	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	433152	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4020325	USD
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	209395	USD
CY2015Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	161460	USD
CY2014Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	23662	USD
CY2015Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	90478	USD
CY2014Q2	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-2387	USD
CY2015Q2	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-5495	USD
CY2014Q2	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	373	USD
CY2015Q2	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	396	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	626554	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	754445	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23662	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	90479	USD
CY2015Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	161460	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	4864426	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	3372646	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4431274	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	2510158	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	78205	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	72683	USD
CY2014Q2	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-1566257	USD
CY2015Q2	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	13642832	USD
CY2014Q2	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1670678	USD
CY2015Q2	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2014Q2	us-gaap	Other Income OtherIncome	3248	USD
CY2015Q2	us-gaap	Other Income OtherIncome	-2750	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29464	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13567399	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-4401810	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	16077557	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	565150231	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	646851543	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	733912128	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	812605460	shares
CY2015Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2040591	USD
CY2015Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	90478	USD
CY2015Q2	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	1199671	USD
CY2014Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	434673	USD
CY2015Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-397822	USD
CY2014Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	593429	USD
CY2015Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-168789	USD
CY2014Q2	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-102513	USD
CY2015Q2	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-148954	USD
CY2014Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	540177	USD
CY2015Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2076625	USD
CY2014Q2	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-3334	USD
CY2015Q2	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-3334	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4212663	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1890837	USD
CY2014Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	678811	USD
CY2015Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	709706	USD
CY2014Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6611	USD
CY2014Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	239564	USD
CY2015Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1199671	USD
CY2015Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6637	USD
CY2014Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	74359	USD
CY2015Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2014Q2	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	5000000	USD
CY2015Q2	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4240219	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-716343	USD
CY2014Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	11498	USD
CY2015Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	90938	USD
CY2014Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9360	USD
CY2015Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1203633	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2977962	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1231189	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4152456	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6941777	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8172966	USD
CY2015Q2	us-gaap	Deferred Long Term Liability Charges DeferredLongTermLiabilityCharges	39119741	USD
CY2015Q1	us-gaap	Deferred Long Term Liability Charges DeferredLongTermLiabilityCharges	52762573	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	272620	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	272620	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6232032	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6074117	USD
CY2015Q2	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	139419	USD
CY2015Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	135874	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	660013790	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631160701	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	659013790	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	630060701	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	16077557	USD
CY2015Q2	us-gaap	License And Maintenance Revenue LicenseAndMaintenanceRevenue	5000000	USD
CY2014Q2	us-gaap	License And Maintenance Revenue LicenseAndMaintenanceRevenue	0	USD
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	165753917	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3317167	shares
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4325000	shares
CY2015Q2	eltp	Park Capital Purchase Agreement ParkCapitalPurchaseAgreement	0	USD
CY2015Q2	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	include an initial term that expires on December 31, 2016, and the Company has the option to renew the lease for two additional terms of five years each
CY2014Q2	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	451271	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2040591	USD
CY2014Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	896613	USD
CY2015Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	37027	USD
CY2015Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-171362	USD
CY2014Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	88314	USD
CY2015Q2	us-gaap	Interest Paid InterestPaid	22552	USD
CY2015Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015Q2	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	USD
CY2014Q2	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	272727	USD
CY2015Q2	eltp	Commitment Shares Issued CommitmentSharesIssued	849897	USD
CY2014Q2	eltp	Commitment Shares Issued CommitmentSharesIssued	653264	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	203850	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	155169	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	359019	USD
CY2015Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45214	USD
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	17789	USD
CY2015Q2	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	573667	USD
CY2014Q2	us-gaap	Interest Paid InterestPaid	77832	USD
CY2014Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014Q2	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-2308216	USD
CY2015Q2	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-6428571	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	2590233	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2850459	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	160394	USD
CY2015Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	58771	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	112586	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	122772	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD

Files In Submission

Name	View Source	Status
0001144204-15-047733-index-headers.html	Edgar Link	pending
0001144204-15-047733-index.html	Edgar Link	pending
0001144204-15-047733.txt	Edgar Link	pending
0001144204-15-047733-xbrl.zip	Edgar Link	pending
eltp-20150630.xml	Edgar Link	completed
eltp-20150630.xsd	Edgar Link	pending
eltp-20150630_cal.xml	Edgar Link	unprocessable
eltp-20150630_def.xml	Edgar Link	unprocessable
eltp-20150630_lab.xml	Edgar Link	unprocessable
eltp-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v416815_10q.htm	Edgar Link	pending
v416815_ex31-1.htm	Edgar Link	pending
v416815_ex31-2.htm	Edgar Link	pending
v416815_ex32-1.htm	Edgar Link	pending
v416815_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2015 Q2 Form 10-Q Financial Statement

#000114420415047733 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2015 Q2 Form 10-Q Financial Statement

#000114420415047733 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp